Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
R&D investments rise to EUR 6.2 billion, 23.2% of group net sales.
Company prepares new product launches starting in 2025.
Dubai, United Arab Emirates – Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion.
'As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,' said Hubertus von Baumbach, Chairman of the Board of Managing Directors. 'It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.'
Strong Growth in IMETA
In India, Middle East, Turkey, and Africa (IMETA) region, the company recorded net sales of 855 million EUR (2023: 732 million EUR), a 17% increase compared to the previous year.
Derek O'Leary, Regional Managing Director at Boehringer Ingelheim India, Middle East, Turkey and Africa (IMETA) said: 'Our strong performance in 2024 underscores our commitment to addressing unmet medical needs in both human and animal health. We will continue to work towards expanding access to innovative treatments for people and strengthen our efforts to safeguard animal health and well-being, impacting a greater number of lives. In partnerhip with our stakeholders, we are eager to build on this momentum in 2025 through further science-backed innovations tailored to the needs of both patients and animals.'
Human Pharma: investing in existing products and new launches
Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by the treatment of chronic kidney diseases, type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. Treatments used for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion.
The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales.
'If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,' said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. 'With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.'
After positive data from pivotal studies, the company is preparing multiple new product launches to advance care for patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis as well as the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients.
Both treatments have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval.
Animal Health: rapid response against transboundary animal diseases
Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion.
Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease. These diseases pose a significant risk to animal health, impede global trade, and constrain food supply.
Sustainable Development
Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs.
As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The 'Angels' initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date.
Outlook
The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects.
* sales growth numbers are adjusted for currency effects
**one-sided p-value from a z-test of the null hypothesis ORR ≤30%
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer Ingelheim - Life Forward | Boehringer Ingelheim.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
06-08-2025
- Gulf Today
How Gulf Millennials are trading like It's Instagram
There was a time when investing was for the lucky few — the rich, the serious, the kind who wore suits to breakfast. Now it's for everyone. Even that twenty-something guy flipping through trading apps in a Sharjah coffee shop, pretending to read poetry. He isn't reading. He's trading — or rather, copying someone else's trade with a single tap. They call it social trading, and Gulf youth are hooked. No all-nighters with charts. No pretending to understand 'Bollinger Bands.' Just find someone who looks like they know what they're doing and copy them, like a recipe from TikTok. Simple. Exciting. Risky It started as whispers: someone's cousin made money in forex; a friend in Dubai cashed out on crypto. People doubted it — 'Just luck,' they said. Then more joined: quiet ones, loud ones, reckless ones. The whispers became movement. A generation raised on Instagram wanted their money to move as fast as their thumbs. Slick apps with shiny charts and 'Top Traders This Week' banners. Users scroll, follow, copy. Wins are thrilling. Losses happen, too — but people keep going. Enter the platforms This isn't only about money; it's about belonging. Open the app and see: 'TraderX is up 28% this month,' with comments and mini fan clubs cheering them on. Trader-influencers are the new reality. 'Buy EUR/USD.' You don't know why — but you click. Social trading is fast, communal, and addictive, like watching reels with cash on the line. The Gulf's young traders want it all now — real-time, bite-sized, and story-driven. Not stiff, calculator finance. They want apps that move like apps, not bank websites from 2003. Stories sell: 'How I made 200 AED in five minutes,' 'Portfolio glow-ups,' lunch-break trades. Social trading adds community to money. A woman shares crypto tips; a guy trades between meetings. Why the Gulf Loves It Little tribes form around risk and reward. Critics call it gambling, and maybe it is — but excitement drives adoption. Behind the scenes, brokerages scramble to adapt. They need platforms that offer copy trading, real-time alerts, and tech that feels effortless. That's where ScaleTrade comes in — giving brokers modular, white label solutions built for this generation. Social trading is about vibe , and ScaleTrade powers it. The future generations come fast, flashy, and maybe wiser. AI may pick your trades in a couple years from now. Apps might warn: 'Too risky.' But once people taste the power to trade, to follow, to win , they won't let go.
Khaleej Times
29-07-2025
- Khaleej Times
Multiply Group posts Dh214 million net profit in second quarter
Multiply Group, a leading Abu Dhabi-based investment holding firm, on Tuesday announced its Q2 2025 net profit at Dh214 million excluding fair value changes, with 39% revenue growth across the operating portfolio. Ebitda excluding fair value changes of stood at Dh395 million (Dh403 million in Q2 2024). Adjusting for the impact of the Kalyon Enerji joint venture (realising a share of loss as a result of foreign exchange losses arising from the revaluation of EUR-dominated loans), the Group's Ebitda rose 38 per cent year-on-year (YoY) for Q2 2025. Net profit from subsidiaries increased 52 per cent underpinned by solid growth across verticals. Reported profit of Dh532 million included Dh318 million in unrealised gains from revaluation, driven by periodic market fluctuations. The Group continues to focus on integrating operations across its verticals, with an emphasis on digital transformation and operational efficiency. These efforts have contributed to strong revenue momentum. Group revenue increased by 39 per cent YoY to Dh503 million, driven by growth across all verticals, the full-quarter consolidation of The Grooming Company Holding and the acquisition of Excellence Driving. Blended gross profit margin remained healthy at 52 per cent, reflecting continued profitability across the core portfolio. The Group's net profit from operating businesses increased by 52 per cent on the back of the Beauty vertical more than doubling net profit and the Mobility vertical increasing net profit by 48 per cent as a result of organic and inorganic growth while Media vertical grew by 23 per cent. The Group recorded a share of loss from Kalyon JV amounting to Dh54 million in Q2 2025 (Q2 2024 - Dh78 million gain) as a result of the foreign exchange losses from the revaluation of EUR-denominated loans on the back of a stronger Euro. The Group's balance sheet remains robust, with cash balance of Dh1.85 billion. Execution of its long-term strategy continues to deliver results, as the Group builds a diversified portfolio across core verticals while pursuing high-return investments under Multiply+ Under Multiply+, the Group's public market portfolio closed the quarter with a valuation of Dh32 billion, compared to an initial investment of Dh15 billion. Despite market fluctuations affecting the fair value of some assets, performance across the portfolio remains strong as does the underlying long-term potential from targeted investments. Samia Bouazza, group chief executive officer and managing director, said: 'This quarter's revenue growth of 39 per cent reflects the strong double-digit performance delivered across all verticals. This momentum translated into a 69 per cent increase in operating Ebitda and a 52 per cent rise in net income from our operating subsidiaries. These gains were partially offset by an adverse Dh132 million impact from our share of profit in the Kalyon joint venture, primarily due to foreign exchange losses arising from the revaluation of EUR-dominated loans. While our inorganic initiatives contributed to the Group's overall growth, organic Ebitda from our operating businesses increased by 54 per cent year-on-year, led by our Media & Mobility Verticals. During the quarter, we also signed a definitive agreement to divest our 100 per cent stake in PAL Cooling Holding, a prominent provider of district cooling solutions in the UAE catering to landmark residential, commercial and mixed-use developments in Abu Dhabi. The transaction, valued at c. Dh3.8 billion, will result in significant cash inflows. These proceeds will be strategically redeployed to support future growth opportunities as we actively evaluate options to optimize our balance sheet and strengthen Multiply Group's capital structure.'
Arabian Business
24-07-2025
- Arabian Business
UK sees 40% surge in tax contributions from wealthy amid rising high-net-worth exodus
Wealthy individuals in the UK have seen their tax burden increase by nearly 40 per cent over the past four years, according to new analysis from investment migration advisory firm Astons. The findings come amid a growing trend of high-net-worth individuals (HNWIs) exiting the country, spurred by tighter non-domicile tax rules and increasingly unfavourable fiscal policy. In its latest analysis of HMRC tax receipt data, Astons reports that wealthy UK residents — defined by HMRC as individuals earning over GBP 200,000 annually or holding assets exceeding GBP 2 million — paid GBP 190 billion in tax during the 2023–24 fiscal year. That figure marks a 3.7 per cent rise from the previous year and a 39.8 per cent increase since 2019–20. Of that total, GBP 69.9 billion was paid through PAYE income tax and GBP 32.9 billion via self-assessment, both categories reflecting a more than 61 per cent increase over the four-year period. Capital gains tax receipts reached GBP 9.5 billion, with inheritance and stamp duties contributing GBP 3.8 billion and GBP 2.9 billion, respectively. The data further shows that wealthy individuals accounted for 88 per cent of all self-assessment income tax receipts collected by HMRC during the period, underlining the significant role HNWIs play in the UK's business and entrepreneurial ecosystem. Astons notes that the increase in tax receipts coincides with sweeping reforms to the UK's non-domicile (non-dom) tax regime, which took effect in April 2025. Under the new rules, aimed at enhancing fairness and transparency, it is estimated that 10 per cent of non-doms have already left the UK as of June, despite a four-year transition period granted to new residents. 'This huge increase in tax being taken from the UK's wealthy population over the past few years goes a long way towards explaining why so many are choosing to leave,' said Alena Lesina, Citizenship and Residency Consultant at Astons. 'There are countries around the world that take a far more supportive and encouraging stance towards wealth creation, recognising the value that high-net-worth individuals bring through job creation, business investment, and wider economic contribution.' Lesina cited Greece's Golden Visa as a standout alternative for wealthy individuals seeking more favourable tax treatment. The programme, which starts at a EUR 250,000 investment threshold, offers residency rights and includes a non-dom regime under which eligible participants can pay a flat annual tax of EUR 100,000 on global income, instead of standard progressive rates that can reach 45 per cent. 'Greek residency also comes with the added benefit of unrestricted travel across the Schengen Zone – a right UK nationals lost post-Brexit,' Lesina said. 'And uniquely, Greece does not require investors to live permanently in the country to maintain their Golden Visa status.'
